In clinical settings, Mutect2 is used to analyze patient tumor samples for actionable mutations. These mutations can inform treatment decisions, such as the selection of targeted therapies or inclusion in clinical trials. For instance, identifying mutations in genes like EGFR or BRCA1 can guide the use of specific inhibitors or recommend genetic counseling for patients and their families.
